Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.In an early phase trial of Provectus Pharmaceuticals cancer compound, PV-10, also known as Provecta, the initial lower dose in the study has been well tolerated by patients with skin cancer.
Subscribe to our email newsletter
The study is being conducted at two dosage levels with both dosage levels having the potential for showing safety, preliminary efficacy, and the “bystander effect.” The authorized dosage will now be increased to the maximum level for treatment of the remaining subjects.
PV-10 is the company’s lead cancer agent and is being evaluated for safety and preliminary efficacy in a total of 20 subjects with stage III metastatic melanoma, which is the most aggressive form of skin cancer. The study is being conducted at two of the world’s leading melanoma treatment and research centers, both located in New South Wales, Australia.
Dr Eric Wachter, executive vice president and head of the company’s pharmaceutical development program, noted, “The initial data is very encouraging and appears comparable to the response we’ve seen in each of our preclinical studies. While this is exciting, it is important to remember that even if this study proves to be successful, further study will be necessary to definitively demonstrate efficacy.”